Disease-Modifying Antirheumatic Drug (DMARD) Market
- 2026 年市場規模
- USD 23.72 Bn
- 2033 年預估規模
- USD 30.18 Bn
- 年複合成長率 CAGR
- 3.5%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Disease-Modifying Antirheumatic Drug (DMARD) Market, By Drug Type (Synthetic (sDMARD) (Conventional synthetic (csDMARDs) (Methotrexate, Sulfasalazine, Leflunomide, Hydroxychloroquine, Gold Salts)), Targeted synthetic DMARDs (tsDMARDs), Biological DMARDs (bDMARD) (Original DMARDs (boDMARDs), Biosimilar DMARDs (bsDMARDs) (Primary, Secondary, Tertiary)), Others), By Route of Administration (Oral, Parenteral, Others), By Indication (Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Systemic Lupus Erythematosus, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)
報告摘要
Disease-modifying anti-rheumatic drugs (DMARDs) can treat the underlying cause of condition and reduce inflammation. They are given to people with autoimmune conditions, such as rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, ankylosing spondylitis and others. These are conditions where the immune system, which normally fights infection, attacks the body’s own healthy tissues. DMARDs can improve symptoms such as pain, stiffness and swelling, but they may take a few weeks or even months to fully take effect. There are different types of DMARDs, and they work in slightly different ways. The three main types are: synthetic (sDMARD), targeted synthetic DMARDs, biological DMARDs (bDMARD) and others
Market Dynamics
Key players operating in the global disease-modifying anti-rheumatic drugs (DMARDs) market are focusing on increasing product launches and product approvals which is expected to drive the market growth during the forecast period. For instance, in January 2018, Hetero, one of the leading generic pharmaceutical companies launched its fourth biosimilar drug ‘Adalimumab’ under the brand name ‘Mabura’ in India. Mabura is an anti-inflammatory biologic medication specific for human tumor necrosis factor (TNF). It is indicated for the treatment of rheumatoid arthritis and other auto-immune disorders such as psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis. Moreover, in September 2020, Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation announced that the U.S. Food and Drug Administration (FDA) approved XELJANZ (tofacitinib) for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). Two formulations were approved, a tablet and an oral solution, and are dosed based upon weight. This approval makes XELJANZ the first and only Janus kinase (JAK) inhibitor approved in the U.S. for the treatment of pcJIA.
Key features of the study
• This report provides an in-depth analysis of the global disease-modifying anti-rheumatic drugs (DMARDs) market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global disease-modifying anti-rheumatic drugs (DMARDs) market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
• Key companies covered as a part of this study include Sanofi., Pfizer, F. Hoffman-La Roche AG, Johnson & Johnson, AbbVie Inc., Eli Lilly & Company, Amgen Inc., Swedish Orphan Biovitrum AB, Bristol-Myers Squibb Company, UCB S.A., Gilead Sciences, Inc., and Cumberland Pharmaceuticals Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global disease-modifying anti-rheumatic drugs (DMARDs) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global disease-modifying anti-rheumatic drugs (DMARDs) market
Market Segmentation
• By Drug Type (Revenue, USD Bn, 2021-2033)
o Synthetic (sDMARD)
Conventional synthetic (csDMARDs)
o Methotrexate
o Sulfasalazine
o Leflunomide
o Hydroxychloroquine
o Gold Salts
o Targeted synthetic DMARDs (tsDMARDs)
o Biological DMARDs (bDMARD)
Original DMARDs (boDMARDs)
Biosimilar DMARDs (bsDMARDs)
Primary
Secondary
Tertiary
o Others
• By Route of Administration (Revenue, USD Bn, 2021-2033)
o Oral
o Parenteral
o Others
• By Indication (Revenue, USD Bn, 2021-2033)
o Rheumatoid Arthritis
o Ankylosing Spondylitis
o Psoriatic Arthritis
o Systemic Lupus Erythematosus
o Others
• By Distribution Channel (Revenue, USD Bn, 2021-2033)
o Hospital Pharmacy
o Retail Pharmacy
o Online Pharmacy
• Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Region (Revenue, USD Bn, 2021-2033)
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Key Players
o Pfizer
o Hoffman-La Roche AG
o Johnson & Johnson
o AbbVie Inc.
o Eli Lilly & Company
o Amgen Inc.
o Swedish Orphan Biovitrum AB
o Bristol-Myers Squibb Company
o UCB S.A.
o Gilead Sciences, Inc.
o Cumberland Pharmaceuticals Inc.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Drug Type
Market Snapshot, By Route of Administration
Market Snapshot, By Indication
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Product Approval
o Collaboration/Merge/Acquisition
o Regulatory Landscape
o PEST Analysis
o Porter’s Five Forces Analysis
o Epidemiology
o Robust Pipeline Analysis
4. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Drug Type, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Synthetic (sDMARD)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Conventional synthetic (csDMARDs)
o Methotrexate
o Sulfasalazine
o Leflunomide
o Hydroxychloroquine
o Gold Salts
o Targeted synthetic DMARDs (tsDMARDs)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Biological DMARDs (bDMARD)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Original DMARDs (boDMARDs)
o Biosimilar DMARDs (bsDMARDs)
o Primary
o Secondary
o Tertiary
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
5. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Route of Administration, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Parenteral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
6. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Indication, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Rheumatoid Arthritis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Ankylosing Spondylitis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Psoriatic Arthritis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Systemic Lupus Erythematosus
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
7. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Distribution Channel, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Hospital Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Retail Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Online Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
8. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Region, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Rout of Administration 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Indication 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Rout of Administration 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Indication 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Rout of Administration 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Indication 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Rout of Administration 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Indication 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Rout of Administration 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Indication 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Rout of Administration 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Indication 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o North Africa
o Central Africa
o South Africa
9. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profile
Sanofi
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Pfizer
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
F. Hoffman-La Roche AG
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Johnson & Johnson
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
AbbVie Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Eli Lilly & Company
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Amgen Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Swedish Orphan Biovitrum AB
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Bristol-Myers Squibb Company
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
UCB S.A.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Gilead Sciences, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Cumberland Pharmaceuticals Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Analyst Views
10. Section
o References
o Research Methodology
o About Us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們